Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered paper session- NSCLC, metastatic

4485 - Primary efficacy results from B-F1RST, a prospective Phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC)

Date

22 Oct 2018

Session

Proffered paper session- NSCLC, metastatic

Topics

Targeted Therapy;  Immunotherapy

Tumour Site

Presenters

Edward Kim

Authors

E.S. Kim1, V. Velcheti2, T. Mekhail3, T.A. Leal4, J.E. Dowell5, M.L. Tsai6, C.S.R. Dakhil7, P. Stella8, V. Shen9, S. Hu10, S.M. Paul11, D.S. Shames11, E. Schleifman12, D.A. Fabrizio13, C. Yun14, S. Phan14, M.A. Socinski15

Author affiliations

  • 1 Dept Of Solid Tumor Oncology And Investigational Therapeutics, Levine Cancer Institute, Atrium Health, Carolinas HealthCare System, NC 28204 - Charlotte/US
  • 2 Hematology And Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland/US
  • 3 Medical Oncology, Florida Hospital Cancer Institute, Orlando/US
  • 4 Division Of Hematology, Oncology, Palliative Care, University of Wisconsin-Madison, School of Medicine and Public Health, Madison/US
  • 5 Department Of Medicine, Veterans Affairs North Texas Healthcare System, University of Texas Southwestern Medical Center, Dallas/US
  • 6 Minneapolis Clinic, Minnesota Oncology, Minneapolis/US
  • 7 Medical Oncology, Cancer Center of Kansas, Wichita/US
  • 8 Medical Oncology, St. Joseph Mercy Hospital, Ann Arbor/US
  • 9 Biometrics, Evidence Generation, Usma, F. Hoffmann-La Roche, Ltd, Mississauga/CA
  • 10 Genentech Usma, Evidence Generation, Biometrics, Genentech, Inc., South San Francisco/US
  • 11 Oncology Biomarker Development, Genentech, Inc., South San Francisco/US
  • 12 Companion Diagnostic Development, Oncology Biomarker Development, Genentech, Inc., South San Francisco/US
  • 13 Medical Oncology, Foundation Medicine, Inc., Cambridge/US
  • 14 Us Medical Affairs, Genentech, Inc., South San Francisco/US
  • 15 Thoracic Oncology Program, Florida Hospital Cancer Institute, Orlando/US
More

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4485

Background

Blood and tissue TMB have shown promise in predicting benefit from PD-L1/PD-1 inhibitors. High bTMB enriched for a PFS benefit in patients (pts) treated with atezo monotherapy in retrospective analyses from the randomized, 2L NSCLC Ph III OAK and Ph II POPLAR studies. We report primary results from the fully enrolled prospective, Ph II, B-F1RST study evaluating a novel bTMB assay as a predictive biomarker for atezo in 1L NSCLC.

Methods

Of 152 ITT pts, 119 comprised the biomarker-evaluable population (BEP) that had adequate circulating tumor (ct)DNA (maximum somatic allele frequency [MSAF] ≥ 1%); 29 had inadequate ctDNA (non-BEP [MSAF <1%]). A prespecified bTMB cutoff (high ≥ 16; low < 16) was used to evaluate clinical efficacy. Coprimary endpoints were ORR and PFS. Statistical tests were 2-sided at a 0.1 level.

Results

With minimum follow-up of ≥6 mo, confirmed ITT ORR was 14.5% (22/152). ORR in BEP was 10.1% (12/119) and non-BEP was 34.5% (10/29). In bTMB high vs low pts, ORR was 28.6% (8/28) vs 4.4% (4/91) and mPFS was 4.6 vs 3.7 mo; HR=0.66 (90% CI, 0.42–1.02; P=0.12). mPFS at exploratory bTMB cutoffs are presented in the Table. bTMB high vs low mOS was NE vs 13.1 mo; HR=0.77 (90% CI, 0.41–1.43; P=0.48). 13% of pts had treatment-related serious AEs and 20% had treatment-related Gr 3/4 AEs. 15% of pts had AEs leading to discontinuation.

Conclusions

The B-F1RST primary analysis is the first full prospective dataset evaluating clinical utility of bTMB as a predictive biomarker for 1L pts receiving atezo monotherapy. Consistent with interim data, pts at the prespecified bTMB ≥16 cut-off had numerical benefit for PFS, ORR and OS. Pts will be followed for ≥18 mo per protocol. Additional exploratory analyses on the bTMB biomarker will be reported.

PFS (mo) by bTMB scores (BEP, n=119)
bTMB Low
(< bTMB cutoff)
bTMB High
(≥ bTMB cutoff)
bTMB cutoff median (n) median (n) HR 90% CI
12 4.1 (75) 2.6 (44) 1.01 0.70, 1.46
14 4.1 (84) 2.6 (35) 0.92 0.62, 1.37
16 3.7 (91) 4.6 (28) 0.66 0.42, 1.02
18 3.2 (96) 6.9 (23) 0.46 0.28, 0.76
20 2.9 (100) 6.9 (19) 0.48 0.28, 0.82

Clinical trial identification

NCT02848651

Editorial Acknowledgement

Christopher Lum, PhD, Health Interactions

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.